VERU

Market-moving news on Veru (NASDAQ: VERU): filings, earnings, deals and other events, from REDFILED.

VERU

VERU Pushes Oral Sabizabulin Into Phase 2 for Daraxonrasib-Resistant Pancreatic Cancer

Veru will seek an FDA pre-IND meeting in Q4 2026 after preclinical data showed sabizabulin remains potent in daraxonrasib-resistant pancreatic cancer cells.

VERU

VERU Pivots Sabizabulin to Pancreatic Cancer After Preclinical Data

Veru will take oral sabizabulin into a planned Phase 2b trial in daraxonrasib-resistant pancreatic cancer and drops its cardiovascular inflammation plan.